Keith Ligon, MD, PhD
Neuropathology, Department of Pathology
Associate Professor of Pathology, Harvard Medical School
Image
Keith Ligon, MD, PhD
Neuropathology, Department of Pathology
Associate Professor of Pathology, Harvard Medical School
Medical Services
Languages
English
Education
Graduate School
PhD
University of Texas Medical School at Houston/MD Anderson Cancer Center
1996
Houston
TX
Medical School
University of Texas Medical School at Houston
1997
Houston
TX
Residency
Anatomic Pathology
Brigham and Women's Hospital
1999
Boston
MA
Fellowship
Neuropathology
Brigham and Women's Hospital/Boston Children's Hospital
2001
Boston
MA
Certifications
American Board of Pathology (Anatomic)
American Board of Pathology (Neuropathology)
Publications
Glioblastoma-instructed astrocytes suppress tumour-specific T cell immunity. View Abstract
High-throughput single-cell density measurements enable dynamic profiling of immune cell and drug response from patient samples. View Abstract
Canonical amplifications and CDKN2A/B loss refine IDH1/2-mutant astrocytoma prognosis. View Abstract
Deciphering the longitudinal trajectories of glioblastoma ecosystems by integrative single-cell genomics. View Abstract
The multilayered transcriptional architecture of glioblastoma ecosystems. View Abstract
Dissecting the immune landscape in pediatric high-grade glioma reveals cell state changes under therapeutic pressure. View Abstract
Investigative needle core biopsies support multimodal deep-data generation in glioblastoma. View Abstract
Phase I Study of Adavosertib with Radiotherapy and Temozolomide in Newly Diagnosed Glioblastoma and Intratumoral Drug Levels in Recurrent Glioblastoma. View Abstract
Effective targeting of PDGFRA-altered high-grade glioma with avapritinib. View Abstract
A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma. View Abstract
Genomic Profiling Reveals SMARCA4 Mutations Are Associated with Shorter Overall and Intracranial Progression-Free Survival in Patients with Melanoma Brain Metastases. View Abstract
Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent Glioblastoma. View Abstract
Increased SOX10, p16, and Cyclin D1 Immunoreactivity Differentiates MAP Kinase-activated Low-grade Gliomas From Piloid Gliosis. View Abstract
Contemporary prognostic signatures and refined risk stratification of gliomas: An analysis of 4400 tumors. View Abstract
Multimodal deep learning improves recurrence risk prediction in pediatric low-grade gliomas. View Abstract
Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: clinical and molecular outcomes of a stage 2 single-arm expansion cohort. View Abstract
Epidermal growth factor receptor and Ink4a/Arf: Convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. View Abstract
A comparative analysis of IDH-mutant glioma in pediatric, young adult, and older adult patients. View Abstract
Pilot Trial of Perampanel on Peritumoral Hyperexcitability in Newly Diagnosed High-grade Glioma. View Abstract
Phase 1b/2 study of orally administered pexidartinib in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma. View Abstract
A pathology foundation model for cancer diagnosis and prognosis prediction. View Abstract
GABAergic neuronal lineage development determines clinically actionable targets in diffuse hemispheric glioma, H3G34-mutant. View Abstract
Author Correction: Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer. View Abstract
Surgical window of opportunity trial reveals mechanisms of response and resistance to navtemadlin (KRT-232) in patients with recurrent glioblastoma. View Abstract
Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer. View Abstract
Velcrin molecular glues induce apoptosis in glioblastomas with high PDE3A and SLFN12 expression. View Abstract
Noninvasive Molecular Subtyping of Pediatric Low-Grade Glioma with Self-Supervised Transfer Learning. View Abstract
Measuring single-cell density with high throughput enables dynamic profiling of immune cell and drug response from patient samples. View Abstract
Pilot trial of perampanel on peritumoral hyperexcitability and clinical outcomes in newly diagnosed high-grade glioma. View Abstract
A heterogeneous pharmaco-transcriptomic landscape induced by targeting a single oncogenic kinase. View Abstract
Targeting TRIP13 in favorable histology Wilms tumor with nuclear export inhibitors synergizes with doxorubicin. View Abstract
Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendroglioma. View Abstract
Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed Glioblastoma. View Abstract
Systematic characterization of antibody-drug conjugate targets in central nervous system tumors. View Abstract
Author Correction: Liquid biopsy epigenomic profiling for cancer subtyping. View Abstract
Glioma genetic profiles associated with electrophysiologic hyperexcitability. View Abstract
Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma. View Abstract
Investigative needle core biopsies for multi-omics in Glioblastoma. View Abstract
Insulin feedback is a targetable resistance mechanism of PI3K inhibition in glioblastoma. View Abstract
Noninvasive molecular subtyping of pediatric low-grade glioma with self-supervised transfer learning. View Abstract
2D and 3D multiplexed subcellular profiling of nuclear instability in human cancer. View Abstract
Liquid biopsy epigenomic profiling for cancer subtyping. View Abstract
Clinical trial links oncolytic immunoactivation to survival in glioblastoma. View Abstract
Single-cell profiling and zebrafish avatars reveal LGALS1 as immunomodulating target in glioblastoma. View Abstract
Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization. View Abstract
Intratumoral drug-releasing microdevices allow in situ high-throughput pharmaco phenotyping in patients with gliomas. View Abstract
ALK Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma. View Abstract
Evaluating hematologic parameters in newly diagnosed and recurrent glioblastoma: Prognostic utility and clinical trial implications of myelosuppression. View Abstract
Machine learning for cryosection pathology predicts the 2021 WHO classification of glioma. View Abstract
Telomerase inhibition is an effective therapeutic strategy in TERT promoter-mutant glioblastoma models with low tumor volume. View Abstract
High-plex immunofluorescence imaging and traditional histology of the same tissue section for discovering image-based biomarkers. View Abstract
(R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers. View Abstract
Dynamic BH3 profiling identifies pro-apoptotic drug combinations for the treatment of malignant pleural mesothelioma. View Abstract
Single-cell molecular profiling using ex vivo functional readouts fuels precision oncology in glioblastoma. View Abstract
Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma. View Abstract
Reduced Levels of Misfolded and Aggregated Mutant p53 by Proteostatic Activation. View Abstract
Glioma genetic profiles associated with electrophysiologic hyperexcitability. View Abstract
Cancer-associated fibroblasts are the main contributors to epithelial-to-mesenchymal signatures in the tumor microenvironment. View Abstract
Multi-institutional study of the frequency, genomic landscape, and outcome of IDH-mutant glioma in pediatrics. View Abstract
Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. View Abstract
Integrated response analysis of pediatric low-grade gliomas during and after targeted therapy treatment. View Abstract
The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location. View Abstract
K27M in canonical and noncanonical H3 variants occurs in distinct oligodendroglial cell lineages in brain midline gliomas. View Abstract
BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma. View Abstract
Improved survival among females and association with lymphopenia in patients with newly diagnosed glioblastoma. View Abstract
VRK1 as a synthetic lethal target in VRK2 promoter-methylated cancers of the nervous system. View Abstract
PD-L1 and PD-1 expression in pediatric central nervous system germ cell tumors. View Abstract
FOXR2 Is an Epigenetically Regulated Pan-Cancer Oncogene That Activates ETS Transcriptional Circuits. View Abstract
De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma. View Abstract
Single cell spatial analysis reveals the topology of immunomodulatory purinergic signaling in glioblastoma. View Abstract
Generation of patient-derived models from a metastatic pediatric diffuse leptomeningeal glioneuronal tumor with KIAA1549::BRAF fusion. View Abstract
Correction to: Early EEG hyperexcitability is associated with decreased survival in newly diagnosed IDH-wildtype glioma. View Abstract
Liquid biopsy detection of genomic alterations in pediatric brain tumors from cell-free DNA in peripheral blood, CSF, and urine. View Abstract
Structural variants shape driver combinations and outcomes in pediatric high-grade glioma. View Abstract
Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making. View Abstract
Early EEG hyperexcitability is associated with decreased survival in newly diagnosed IDH-wildtype glioma. View Abstract
A molecularly integrated grade for meningioma. View Abstract
Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients. View Abstract
Synthetic extracellular matrices and astrocytes provide a supportive microenvironment for the cultivation and investigation of primary pediatric gliomas. View Abstract
DICER1 mutations in primary central nervous system tumors: new insights into histologies, mutations, and prognosis. View Abstract
PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation. View Abstract
The Alliance AMBUSH Trial: Rationale and Design. View Abstract
Multimodal platform for assessing drug distribution and response in clinical trials. View Abstract
Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results. View Abstract
Mutational burden and immune recognition of gliomas. View Abstract
Functional drug susceptibility testing using single-cell mass predicts treatment outcome in patient-derived cancer neurosphere models. View Abstract
Molecular Alterations in Pediatric Low-Grade Gliomas That Led to Death. View Abstract
Quantification of aneuploidy in targeted sequencing data using ASCETS. View Abstract
Rates and Patterns of Clonal Oncogenic Mutations in the Normal Human Brain. View Abstract
Prognostication for meningiomas: H3K27me3 to the rescue? View Abstract
Effect of PIK3CA variants on glioma-related epilepsy and response to treatment. View Abstract
IDH-mutant gliomas with additional class-defining molecular events. View Abstract
Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. View Abstract
Targeting glioblastoma using a novel peptide specific to a deglycosylated isoform of brevican. View Abstract
Socioeconomic Disparities Associated With MGMT Promoter Methylation Testing for Patients With Glioblastoma. View Abstract
Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis. View Abstract
Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma. View Abstract
Loss of histone H3 trimethylation on lysine 27 and nuclear expression of transducin-like enhancer 1 in primary intracranial sarcoma, DICER1-mutant. View Abstract
Subependymal giant cell astrocytomas are characterized by mTORC1 hyperactivation, a very low somatic mutation rate, and a unique gene expression profile. View Abstract
Divergent Roles of PI3K Isoforms in PTEN-Deficient Glioblastomas. View Abstract
Epigenomic programming in early fetal brain development. View Abstract
Molecular and clinicopathologic features of gliomas harboring NTRK fusions. View Abstract
Single-Cell RNA-Seq Reveals Cellular Hierarchies and Impaired Developmental Trajectories in Pediatric Ependymoma. View Abstract
Tumor Interferon Signaling Is Regulated by a lncRNA INCR1 Transcribed from the PD-L1 Locus. View Abstract
Prediction of Outcomes with a Computational Biology Model in Newly Diagnosed Glioblastoma Patients Treated with Radiation Therapy and Temozolomide. View Abstract
MR Imaging Correlates for Molecular and Mutational Analyses in Children with Diffuse Intrinsic Pontine Glioma. View Abstract
Mechanisms and therapeutic implications of hypermutation in gliomas. View Abstract
WNT-Activated Medulloblastomas With Hybrid Molecular Subtypes. View Abstract
Correction: BPTF regulates growth of adult and pediatric high-grade glioma through the MYC pathway. View Abstract
Early TP53 alterations engage environmental exposures to promote gastric premalignancy in an integrative mouse model. View Abstract
The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. View Abstract
A large peptidome dataset improves HLA class I epitope prediction across most of the human population. View Abstract
BPTF regulates growth of adult and pediatric high-grade glioma through the MYC pathway. View Abstract
Implementing Patient-Derived Xenografts to Assess the Effectiveness of Cyclin-Dependent Kinase Inhibitors in Glioblastoma. View Abstract
Longitudinal molecular trajectories of diffuse glioma in adults. View Abstract
Increasing value of autopsies in patients with brain tumors in the molecular era. View Abstract
Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course. View Abstract
Pineal apoplexy due to pleomorphic variant pineocytoma. View Abstract
Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma. View Abstract
Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells. View Abstract
Tie2-FGFR1 Interaction Induces Adaptive PI3K Inhibitor Resistance by Upregulating Aurora A/PLK1/CDK1 Signaling in Glioblastoma. View Abstract
Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial. View Abstract
Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations. View Abstract
Resolving medulloblastoma cellular architecture by single-cell genomics. View Abstract
An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. View Abstract
Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma. View Abstract
Clinical Importance of CDKN2A Loss and Monosomy 10 in Pilocytic Astrocytoma. View Abstract
Recurrent EP300-BCOR Fusions in Pediatric Gliomas With Distinct Clinicopathologic Features. View Abstract
Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma. View Abstract
CHD4 regulates the DNA damage response and RAD51 expression in glioblastoma. View Abstract
Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition. View Abstract
Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. View Abstract
The functional synergism of microRNA clustering provides therapeutically relevant epigenetic interference in glioblastoma. View Abstract
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. View Abstract
miR-4516 predicts poor prognosis and functions as a novel oncogene via targeting PTPN14 in human glioblastoma. View Abstract
Linking single-cell measurements of mass, growth rate, and gene expression. View Abstract
Mismatch repair deficiency in high-grade meningioma: a rare but recurrent event associated with dramatic immune activation and clinical response to PD-1 blockade. View Abstract
Microfluidic active loading of single cells enables analysis of complex clinical specimens. View Abstract
The secreted glycolytic enzyme GPI/AMF stimulates glioblastoma cell migration and invasion in an autocrine fashion but can have anti-proliferative effects. View Abstract
Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma. View Abstract
Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma. View Abstract
Correction to: DNA methylation-based reclassification of olfactory neuroblastoma. View Abstract
Vemurafenib and cobimetinib overcome resistance to vemurafenib in BRAF-mutant ganglioglioma. View Abstract
A PDGFRa-driven mouse model of glioblastoma reveals a stathmin1-mediated mechanism of sensitivity to vinblastine. View Abstract
The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) resource in neuro-oncology. View Abstract
Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. View Abstract
Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort. View Abstract
Dual HDAC and PI3K Inhibition Abrogates NF?B- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas. View Abstract
DNA methylation-based reclassification of olfactory neuroblastoma. View Abstract
Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. View Abstract
Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. View Abstract
Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. View Abstract
Immunophenotyping of pediatric brain tumors: correlating immune infiltrate with histology, mutational load, and survival and assessing clonal T cell response. View Abstract
Residual Convolutional Neural Network for the Determination of IDH Status in Low- and High-Grade Gliomas from MR Imaging. View Abstract
A novel GIT2-BRAF fusion in pilocytic astrocytoma. View Abstract
Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma. View Abstract
Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab alone. View Abstract
Nuclear CRX and FOXJ1 Expression Differentiates Non-Germ Cell Pineal Region Tumors and Supports the Ependymal Differentiation of Papillary Tumor of the Pineal Region. View Abstract
Brainstem angiocentric gliomas with MYB-QKI rearrangements. View Abstract
Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. View Abstract
Glioblastoma targeted therapy: updated approaches from recent biological insights. View Abstract
Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. View Abstract
Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma. View Abstract
Clinical Identification of Oncogenic Drivers and Copy-Number Alterations in Pituitary Tumors. View Abstract
Post-translational Modifications of OLIG2 Regulate Glioma Invasion through the TGF-ß Pathway. View Abstract
Pediatric low-grade gliomas: implications of the biologic era. View Abstract
A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas. View Abstract
Intracranial myxoid mesenchymal tumors with EWSR1-CREB family gene fusions: myxoid variant of angiomatoid fibrous histiocytoma or novel entity? View Abstract
Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. View Abstract
A Sequentially Priming Phosphorylation Cascade Activates the Gliomagenic Transcription Factor Olig2. View Abstract
Nuclear inclusion bodies of mutant and wild-type p53 in cancer: a hallmark of p53 inactivation and proteostasis remodelling by p53 aggregation. View Abstract
G1 cyclins link proliferation, pluripotency and differentiation of embryonic stem cells. View Abstract
Multi-omics analysis of primary glioblastoma cell lines shows recapitulation of pivotal molecular features of parental tumors. View Abstract
Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate. View Abstract
Tyrosine receptor kinase B is a drug target in astrocytomas. View Abstract
Post-translational Modifications of OLIG2 Regulate Glioma Invasion through the TGF-ß Pathway. View Abstract
Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas. View Abstract
Glioproliferative Lesion of the Spinal Cord as a Complication of "Stem-Cell Tourism". View Abstract
Genomic characterization of recurrent high-grade astroblastoma. View Abstract
MAPK activation and HRAS mutation identified in pituitary spindle cell oncocytoma. View Abstract
Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. View Abstract
Control of glioblastoma tumorigenesis by feed-forward cytokine signaling. View Abstract
Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma. View Abstract
Disseminated glioneuronal tumors occurring in childhood: treatment outcomes and BRAF alterations including V600E mutation. View Abstract
Decreased FOXJ1 expression and its ciliogenesis programme in aggressive ependymoma and choroid plexus tumours. View Abstract
MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. View Abstract
Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. View Abstract
Case Report: Next generation sequencing identifies a NAB2-STAT6 fusion in Glioblastoma. View Abstract
Myxopapillary ependymomas in children: imaging, treatment and outcomes. View Abstract
Targetable genetic features of primary testicular and primary central nervous system lymphomas. View Abstract
A Brain Tumor/Organotypic Slice Co-culture System for Studying Tumor Microenvironment and Targeted Drug Therapies. View Abstract
Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. View Abstract
Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas. View Abstract
Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. View Abstract
Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. View Abstract
Somatic mutations associated with MRI-derived volumetric features in glioblastoma. View Abstract
A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma. View Abstract
Rapid Intraoperative Molecular Characterization of Glioma. View Abstract
Integrated Genomic Characterization of a Pineal Parenchymal Tumor of Intermediate Differentiation. View Abstract
One size should not fit all: advancing toward personalized glioblastoma therapy. View Abstract
Toward precision medicine in glioblastoma: the promise and the challenges. View Abstract
A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. View Abstract
Calibrating genomic and allelic coverage bias in single-cell sequencing. View Abstract
SHMT2 drives glioma cell survival in ischaemia but imposes a dependence on glycine clearance. View Abstract
Hypofractionated versus standard radiation therapy with or without temozolomide for older glioblastoma patients. View Abstract
Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype. View Abstract
Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. View Abstract
Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. View Abstract
Intermediate DNA methylation is a conserved signature of genome regulation. View Abstract
BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. View Abstract
Temozolomide resistance in glioblastoma occurs by miRNA-9-targeted PTCH1, independent of sonic hedgehog level. View Abstract
Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. View Abstract
Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. View Abstract
A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. View Abstract
A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastoma. View Abstract
Angiomatous meningiomas have a distinct genetic profile with multiple chromosomal polysomies including polysomy of chromosome 5. View Abstract
Interrogation of gossypol therapy in glioblastoma implementing cell line and patient-derived tumour models. View Abstract
Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma. View Abstract
Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas. View Abstract
Molecular pathologic diagnosis of epidermal growth factor receptor. View Abstract
Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas. View Abstract
Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas. View Abstract
Prominin-1 (CD133) defines both stem and non-stem cell populations in CNS development and gliomas. View Abstract
Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group. View Abstract
Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. View Abstract
Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. View Abstract
Immune checkpoint blockade for glioblastoma: preclinical activity of single agent and combinatorial therapy. View Abstract
Phase ii trial of the phosphatidyinositol-3 kinase (pi3k) inhibitor buparlisib (bkm120) in recurrent glioblastoma conducted by the ivy foundation early phase clinical trials consortium. View Abstract
Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery. View Abstract
EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. View Abstract
Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. View Abstract
Temozolomide resistance in glioblastoma cells occurs partly through epidermal growth factor receptor-mediated induction of connexin 43. View Abstract
Tumor associated seizures in glioblastomas are influenced by survival gene expression in a region-specific manner: a gene expression imaging study. View Abstract
SOX2 and p63 colocalize at genetic loci in squamous cell carcinomas. View Abstract
D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. View Abstract
Pediatric low-grade gliomas: how modern biology reshapes the clinical field. View Abstract
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. View Abstract
ZFHX4 interacts with the NuRD core member CHD4 and regulates the glioblastoma tumor-initiating cell state. View Abstract
Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. View Abstract
Pten loss in Olig2 expressing neural progenitor cells and oligodendrocytes leads to interneuron dysplasia and leukodystrophy. View Abstract
Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. View Abstract
Delivery of Functional Anti-miR-9 by Mesenchymal Stem Cell-derived Exosomes to Glioblastoma Multiforme Cells Conferred Chemosensitivity. View Abstract
Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities. View Abstract
Rapid, label-free detection of brain tumors with stimulated Raman scattering microscopy. View Abstract
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. View Abstract
Functional DNA methylation differences between tissues, cell types, and across individuals discovered using the M&M algorithm. View Abstract
Estimating absolute methylation levels at single-CpG resolution from methylation enrichment and restriction enzyme sequencing methods. View Abstract
DNA hypomethylation within specific transposable element families associates with tissue-specific enhancer landscape. View Abstract
Enhancing radiation therapy for patients with glioblastoma. View Abstract
Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. View Abstract
Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. View Abstract
PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma. View Abstract
Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. View Abstract
Ambient mass spectrometry for the intraoperative molecular diagnosis of human brain tumors. View Abstract
Somatic mutations of PIK3R1 promote gliomagenesis. View Abstract
Integrative functional genomics identifies RINT1 as a novel GBM oncogene. View Abstract
Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumors. View Abstract
Brain and testicular tumors in mice with progenitor cells lacking BAX and BAK. View Abstract
BRAF duplications and MAPK pathway activation are frequent in gliomas of the optic nerve proper. View Abstract
Prospective, high-throughput molecular profiling of human gliomas. View Abstract
Zebrafish neurofibromatosis type 1 genes have redundant functions in tumorigenesis and embryonic development. View Abstract
DNA fragmentation simulation method (FSM) and fragment size matching improve aCGH performance of FFPE tissues. View Abstract
Initial treatment patterns over time for anaplastic oligodendroglial tumors. View Abstract
Current clinical development of PI3K pathway inhibitors in glioblastoma. View Abstract
Emerging insights into the molecular and cellular basis of glioblastoma. View Abstract
Somatic activation of AKT3 causes hemispheric developmental brain malformations. View Abstract
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. View Abstract
Neoplastic cells are a rare component in human glioblastoma microvasculature. View Abstract
Classifying human brain tumors by lipid imaging with mass spectrometry. View Abstract
Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas. View Abstract
Maintenance of tumor initiating cells of defined genetic composition by nucleostemin. View Abstract
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. View Abstract
Human glioma growth is controlled by microRNA-10b. View Abstract
BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. View Abstract
Glioma models: new GEMMs add "class" with genomic and expression correlations. View Abstract
The central nervous system-restricted transcription factor Olig2 opposes p53 responses to genotoxic damage in neural progenitors and malignant glioma. View Abstract
Development of stereotactic mass spectrometry for brain tumor surgery. View Abstract
Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. View Abstract
Discrimination of human astrocytoma subtypes by lipid analysis using desorption electrospray ionization imaging mass spectrometry. View Abstract
Epidermal growth factor receptor gene amplification in atypical adenomatous hyperplasia of the lung. View Abstract
Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. View Abstract
Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence. View Abstract
Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). View Abstract
CRX is a diagnostic marker of retinal and pineal lineage tumors. View Abstract
Profiling critical cancer gene mutations in clinical tumor samples. View Abstract
FoxOs cooperatively regulate diverse pathways governing neural stem cell homeostasis. View Abstract
Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss. View Abstract
Myelin gene regulatory factor is a critical transcriptional regulator required for CNS myelination. View Abstract
Array-based genomics in glioma research. View Abstract
Pten and p53 converge on c-Myc to control differentiation, self-renewal, and transformation of normal and neoplastic stem cells in glioblastoma. View Abstract
A novel TP53 germline mutation in a family with a history of multiple malignancies: case report and review of the literature. View Abstract
Phase II study of protracted daily temozolomide for low-grade gliomas in adults. View Abstract
Meningioangiomatosis associated with meningioma: a case report. View Abstract
p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. View Abstract
Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma. View Abstract
Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. View Abstract
Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. View Abstract
Myelin abnormalities without oligodendrocyte loss in periventricular leukomalacia. View Abstract
Malignant astrocytic glioma: genetics, biology, and paths to treatment. View Abstract
Impaired human hippocampal neurogenesis after treatment for central nervous system malignancies. View Abstract
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. View Abstract
Embryonic stem cell transcription factor signatures in the diagnosis of primary and metastatic germ cell tumors. View Abstract
Expression of p16Ink4a compensates for p18Ink4c loss in cyclin-dependent kinase 4/6-dependent tumors and tissues. View Abstract
Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. View Abstract
Disruption of diacylglycerol kinase delta (DGKD) associated with seizures in humans and mice. View Abstract
Semiautomated multiplexed quantum dot-based in situ hybridization and spectral deconvolution. View Abstract
Comparative analysis of germ cell transcription factors in CNS germinoma reveals diagnostic utility of NANOG. View Abstract
Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2. View Abstract
Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. View Abstract
A novel somatic mouse model to survey tumorigenic potential applied to the Hedgehog pathway. View Abstract
p16INK4a induces an age-dependent decline in islet regenerative potential. View Abstract
Olig gene function in CNS development and disease. View Abstract
Development of NG2 neural progenitor cells requires Olig gene function. View Abstract
Evidence for motoneuron lineage-specific regulation of Olig2 in the vertebrate neural tube. View Abstract
Histology-based expression profiling yields novel prognostic markers in human glioblastoma. View Abstract
Diffusion-weighted imaging of fungal cerebral infection. View Abstract
Molecular diversity of astrocytes with implications for neurological disorders. View Abstract
The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas. View Abstract
Loss of Emx2 function leads to ectopic expression of Wnt1 in the developing telencephalon and cortical dysplasia. View Abstract
Arginase deficiency with lethal neonatal expression: evidence for the glutamine hypothesis of cerebral edema. View Abstract
Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. View Abstract
Cooperative transcriptional activation by the neurogenic basic helix-loop-helix protein MASH1 and members of the myocyte enhancer factor-2 (MEF2) family. View Abstract
Paraxis: a basic helix-loop-helix protein expressed in paraxial mesoderm and developing somites. View Abstract
Scleraxis: a basic helix-loop-helix protein that prefigures skeletal formation during mouse embryogenesis. View Abstract
Smooth muscle myosin heavy chain exclusively marks the smooth muscle lineage during mouse embryogenesis. View Abstract
Detection of p53 alterations in human astrocytomas using frozen tissue sections for the polymerase chain reaction. View Abstract
Locations